Join to View Full Profile
1400 NW 12th AveMiami, FL 33136
Phone+1 305-243-5321
Dr. Green is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Damian Green, MD is the Ron and Nedra Kalish Family Endowed Chair in Stem Cell Transplantation, Professor of Medicine and Chief of the Division of Transplantation and Cellular Therapy at the University of Miami and Sylvester Comprehensive Cancer Center. He is also Assistant Director of Translational Research. He has over 20 years of experience treating patients with blood cancer, maintaining a specialized focus on multiple myeloma, B cell lymphoma, stem cell transplant and immunotherapy. He has numerous high impact publications (e.g. Blood, Lancet Oncology, Science Immunology). He is engaged in patient care through outpatient clinic, and managing inpatient bone marrow transplant and immunotherapy teams. His NIH funded laboratory is focused on developing new and more effective forms of immunotherapy. He also runs clinical trials, including first-in-human studies based on findings arising from the laboratory. Prior to joining Sylvester, he led the translational multiple myeloma program at the University of Washington and Fred Hutchinson Cancer Center in Seattle. He earned his medical degree from Ohio State University College of Medicine in 2000 and completed his residency in internal medicine at Ohio State University Hospital from 2000 to 2003. He was then Chief Resident at Ohio State and subsequently pursued further specialization with a fellowship in hematology and medical oncology at the University of Washington from 2004 to 2006.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2004 - 2006
Ohio State University HospitalChief Residency, Internal Medicine, 2003 - 2004- Ohio State University HospitalResidency, Internal Medicine, 2000 - 2003
- Ohio State University College of MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2024 - 2026
WA State Medical License 2004 - 2024
MT State Medical License 2021 - 2021
OH State Medical License 2000 - 2005
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2016 Dec 01
- Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma Start of enrollment: 2017 Nov 29
Publications & Presentations
PubMed
- Hallmarks of terminal T-cell exhaustion are absent in multiple myeloma from diagnosis through maintenance therapy.Carolyn Shasha, David R Glass, Ernest Moelhman, Laura Islas, Yuan Tian
Blood. 2025-03-31 - Development and validation of predictive models of early immune effector cell-associated hematotoxicity.Emily C Liang, Jennifer J Huang, Andrew J Portuguese, Valentín Ortiz-Maldonado, Aya Albittar
Blood Advances. 2025-02-11 - 1 citationsSingle-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy.David G Coffey, Pinar Ataca Atilla, Erden Atilla, Ola Landgren, Andrew J Cowan
Blood. 2025-01-09
Journal Articles
- Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple MyelomaParameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
Abstracts/Posters
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple MyelomaDamian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019- Tip Sheet: Understanding How the Flu Virus Works; Addressing Global Health Challenges in Sub-Saharan Africa; And Using Radioimmunotherapy to Destroy Multiple Myeloma CellsSeptember 5th, 2019
Fred Hutch at ASH: Press Briefing on CAR T-cell Therapy, CRISPR for Blood Disorders, MoreNovember 26th, 2018- Join now to see all
Grant Support
- Radioimmunotherapy Combinations for B-cell MalignancyUNIVERSITY OF MIAMI SCHOOL OF MEDICINE2024–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
